Author name: Leonardo Arias

Challenges in the electrophysiology and Watchman businesses led the medtech company to cut its sales and earnings per share forecasts for the second quarter in a row.

Facing competition from Edwards, Abbott is studying TriClip’s real-world safety and performance in about 1,000 patients.

Biogen officially began reporting revenue from the $5.6 billion acquisition of Apellis in the second quarter, shaking up analysts’ consensus estimates and leading to a beat.

Looking for a biopharma job in New York? Check out the BioSpace list of seven companies hiring life sciences professionals like you.

Business stage is just one factor in whether biopharmas want job candidates to have oncology experience for oncology roles. Two recruiters explain when oncology expertise matters most, the mistakes job seekers make and how to make a good impression.

ElevateBio will be the primary source of Kyverna’s autologous CAR-T cell therapy for anticipated U.S. and global launches in autoimmune indications.

Shareholders allege that Novo Nordisk withheld information about crucial protocol changes in a Phase 3 study of the weight loss drug CagriSema, which led investors to buy company shares “at artificially inflated prices.”

Investors are focused on Incyte’s late-stage programs as the biotech braces for the 2028 patent cliff of its leading product Jakafi.

The FDA published briefing documents ahead of advisory committee meetings for therapies from Capricor Therapeutics and Replimune indicate an uphill battle for the biotechs; GSK and AstraZeneca outline ambitious plans in second quarter presentations; Sarepta taps Michael Severino as its new CEO; and Amgen launches its official defense of Tavneos.

A finales del siglo XIX, la medicina tenía un límite invisible pero frustrante: el corazón humano. Los médicos sabían que este músculo vital funcionaba como una bomba perfecta, y sospechaban que su latido generaba sutiles corrientes eléctricas. Sin em …